BIOVICA INTL. SK-07
Biovica International AB (publ), a biotech company, develops and commercializes novel blood-based biomarker assays that enhance the monitoring and predicting of cancer therapies in the European Union, United States of America, and internationally. It primarily focuses on breast cancer. The company develops DiviTum TKa, a blood-based biomarker assay that measures thymidine kinase activity, which i… Read more
Market Cap & Net Worth: BIOVICA INTL. SK-07 (9II)
BIOVICA INTL. SK-07 (F:9II) has a market capitalization of $740.57K (€721.47K) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #36918 globally and #4631 in its home market, demonstrating a 1200.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying BIOVICA INTL. SK-07's stock price €0.00 by its total outstanding shares 277487223 (277.49 Million).
BIOVICA INTL. SK-07 Market Cap History: 2020 to 2026
BIOVICA INTL. SK-07's market capitalization history from 2020 to 2026. Data shows change from $1.45 Billion to $740.57K (-75.65% CAGR).
BIOVICA INTL. SK-07 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how BIOVICA INTL. SK-07's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 9II by Market Capitalization
Companies near BIOVICA INTL. SK-07 in the global market cap rankings as of March 19, 2026.
Key companies related to BIOVICA INTL. SK-07 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
BIOVICA INTL. SK-07 Historical Marketcap From 2020 to 2026
Between 2020 and today, BIOVICA INTL. SK-07's market cap moved from $1.45 Billion to $ 740.57K, with a yearly change of -75.65%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €740.57K | +116.67% |
| 2025 | €341.80K | -99.08% |
| 2024 | €37.26 Million | -38.74% |
| 2023 | €60.81 Million | -68.56% |
| 2022 | €193.40 Million | -81.82% |
| 2021 | €1.06 Billion | -26.76% |
| 2020 | €1.45 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of BIOVICA INTL. SK-07 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $740.57K USD |
| MoneyControl | $740.57K USD |
| MarketWatch | $740.57K USD |
| marketcap.company | $740.57K USD |
| Reuters | $740.57K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.